Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy

Record ID 32016000750
Authors' recommendations: Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. There are many types of breast cancer. Triple negative is a form of breast cancer that does not respond to hormone treatments or other newer targeted treatments. Veliparib is a new treatment for women with early-stage triple negative breast cancer. Veliparib is given as a tablet taken twice daily. It is given in combination with the chemotherapy drugs carboplatin every 3 weeks and paclitaxel weekly, which are both given directly into the blood. Studies at the moment are aiming to show how well these treatments work together and that veliparib is safe to use. If veliparib is licensed for use in the UK, it will provide a new treatment option for patients with early-stage breast cancer.
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Humans
  • Benzimidazoles
  • Carboplatin
  • Neoadjuvant Therapy
  • Paclitaxel
  • Triple Negative Breast Neoplasms
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.